Engineering virus-like particles as vaccine platforms

By Kathryn M. Frietze, D. Peabody, B. Chackerian. 2016

200 citations recorded by the source corpus.

Virus-like particles (VLPs) have been utilized as vaccine platforms to increase the immunogenicity of heterologous antigens. A variety of diverse VLP types can serve as vaccine platforms, and research has focused on engineering VLPs to improve their efficacy as vaccines, enhance their stability, and allow for more versatile display of antigens. Here, we review selected VLP vaccine platforms, highlight efforts to improve these platforms through structure-informed rational design, and point to areas of future research that will assist in these efforts.

Subfields: Ecology, Epidemiology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ecology

1. David Baker
2. Neil P. King
3. William F. DeGrado
4. I. Korendovych

In Epidemiology

1. F. Sallusto
2. A. Lanzavecchia
3. D. Veesler

Citations in the corpus

• Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus (2019, positive): “…increased antigen density and immunogenicity agrees with previous work using other multivalent antigen presentation platforms (for review, see Frietze et al., 2016; López-Sagaseta et al., 2015) and supports the notion that efficient cross-linking of BCRs by high-density antigen arrays is a…”